spacer
home > ebr > summer 2002 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As the corporate world reels from yet another accounting scandal in the shape of WorldCom, the biotech sector is suffering its own particular crisis in the light of insider trading allegations at ImClone and the deepening crisis of Elan's cash position. Times are not good for those seeking a glimmer of hope in the IPO market, despite several good companies waiting in the wings for an improvement. Tense times seem to bring intense activity as companies tighten their cash burn rates, intensify partnering efforts and perhaps start to look more realistically at M&A as a means of survival. Consolidation can broaden internal R&D expertise towards product-engine capability, strengthen development candidate portfolios and build the essential critical mass deemed necessary for IPO and post-listing survival. The 'hybrid model' - platform technologies with a clear path to products - is what investors are looking for, as evidenced recently in numerous sessions at EC21 and BIO. Following this theme, alternative methods of financing for early stage life science companies is a subject explored in some depth in this issue, through the article from Martin Austin of Paul Capital Partners.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Distributor Oppurtunities

Have an appetite for success – Want to expand your product portfolio – Fancy being part of something special??
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement